Pilot and Randomized, Controlled Studies to Assess Stool Frequency of COVID + Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol): SABER-C and Lite-SABER-C (Specific Administration of Bismuth for Early Recovery of COVID-19)
Phase: PHASE4
Conditions: Diarrhea, COVID-19
Sponsor: University of Cincinnati

CLINICAL PROTOCOL NCTO4811339
A 3 day open label, Pilot study followed by an-up to 21 day double-blind study to assess stool 
frequency ofCOVID + patients treated with oral bismuth subsalicylate (Pepto-Bismol): 
SABER-C 
(Specific Administration of Bismuth for Early Recovery of COVID-19) 
PROTOCOL DA TE: 
DEVELOPMENT PHASE: 
PRODUCTS: 
INVESTIGATORS: 
Version Date: 1, 1312021 v9 
13JAN202l 
IV 
Chewable Pepto-bismol (bismuth subsalicylate tablets) 
and matched placebo 
Dr. Bruce Y acyshyn (PD 
Dr James Collins (co-Investigator) 
550 South Hancock 
CTR building 
UniveFSity of Louisvi Ile 
Louisville, KY 402.02